No biotech company is too big to be bought, at least according to one veteran healthcare executive. David Snow, chief executive of Medco Health Solutions (MHS.N), sees major drugmakers needing the growth potential of biotech more than ever. So expect more large deals like Sanofi’s (SASY.PA) $20.1 billion purchase of Genzyme, he says. That runs counter to what drug executives and bankers are willing to say publicly. They often describe modest deal goals, with price tags under $5 billion, for fear of inflating already lofty valuations.
